Genmab A/S's latest marketcap:
As of 07/05/2025, Genmab A/S's market capitalization has reached $12.61 B. According to our data, Genmab A/S is the 1592th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 12.61 B |
| Revenue (ttm) | 3.23 B |
| Net Income (ttm) | 1.14 B |
| Shares Out | 63.34 M |
| EPS (ttm) | 18.36 |
| Forward PE | 12.26 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/07/2025 |
Genmab A/S's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | $12.61 B | -2.7% | 1592 |
| 12/31/2024 | $13.81 B | -34.35% | 1303 |
| 12/29/2023 | $21.04 B | -24.6% | 853 |
| 12/30/2022 | $27.9 B | 7.47% | 605 |
| 12/31/2021 | $25.96 B | -1.89% | 781 |
| 12/31/2020 | $26.46 B | 84.27% | 672 |
| 12/31/2019 | $14.36 B | 35.31% | 962 |
| 12/31/2018 | $10.61 B | -0.44% | 1064 |
| 12/29/2017 | $10.66 B | -0.04% | 1218 |
| 12/30/2016 | $10.66 B | 23.74% | 942 |
Company Profile
About Genmab A/S
Genmab A/S is a biotechnology company based in Copenhagen, Denmark, specializing in the development of antibody-based therapies for cancer and other diseases. Founded in 1998, the company focuses on innovative treatments to improve patient outcomes.
Key Products
- EPKINLY & TEPKINLY: For adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL).
- Tivdak: For recurrent/metastatic cervical cancer patients with disease progression post-chemotherapy.
- DARZALEX/DARZALEX FASPRO: For multiple myeloma (MM) and light-chain Amyloidosis.
- RYBREVANT: For non-small cell lung cancer (NSCLC).
- TECVAYLI & TALVEY: For relapsed/refractory multiple myeloma (R/R MM).
- Kesimpta: For relapsing multiple sclerosis.
- TEPEZZA: For thyroid eye disease.
Pipeline & Development
Genmab is advancing a robust pipeline of therapies, including:
- Epcoritamab: Targeting DLBCL, FL, B-cell non-Hodgkin lymphoma, and other B-cell malignancies.
- Tisotumab Vedotin: For solid tumors.
- Acasunlimab: For NSCLC and solid tumors.
- Rinatabart Sesutecan: For platinum-resistant ovarian cancer.
- GEN1042, GEN1059, GEN1055, GEN1057: For solid tumors.
- GEN3014: For hematologic malignancies.
- Amivantamab: For head and neck cancer and colorectal cancer.
- Mim8: For hemophilia A.
Strategic Collaborations
Genmab partners with leading pharmaceutical companies, including:
- AbbVie Inc.
- Pfizer Inc.
- BioNTech SE
- Johnson & Johnson
- Novartis International AG
- Bristol Myers Squibb
- Novo Nordisk A/S
With a commitment to cutting-edge research, Genmab continues to expand its portfolio and improve treatment options for patients worldwide.
Frequently Asked Questions
-
What is Genmab A/S's (GMAB) current market cap?As of 07/05/2025, Genmab A/S (including the parent company, if applicable) has an estimated market capitalization of $12.61 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Genmab A/S (GMAB) rank globally by market cap?Genmab A/S global market capitalization ranking is approximately 1592 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.